Oakville, Ontario — November 18, 2025 — Leads & Copy — FORUS Therapeutics announced that XPOVIO® (selinexor) is now publicly funded in Quebec for the treatment of multiple myeloma, effective November 6, 2025.
Kevin Leshuk, President and CEO of FORUS, expressed the company’s pleasure in successfully concluding the INESSS process, stating that this milestone ensures Quebec multiple myeloma patients have equitable access to XPOVIO.
Martine Elias, M.Sc., CEO of Myeloma Canada, commended Quebec’s decision to fund XPOVIO, noting that as an innovative therapy with a novel mechanism of action for patients with early relapsed or refractory disease, XPOVIO offers renewed hope and expands the treatment options available to clinicians and patients.
FORUS Therapeutics is a Canadian biopharmaceutical company focused on developing differentiated medicines for hematologic malignancies and other cancers. The company’s mission is to provide solutions to cancer patients, caregivers, physicians, and partners by accelerating unique treatments that enhance life.
For full funding criteria, refer to the Régie de l’assurance maladie du Québec (RAMQ) at Liste des médicaments fournis en établissement and Liste des médicaments.
For more information and media inquiries, contact Kevin Leshuk, President and CEO, FORUS Therapeutics Inc. at media@forustherapeutics.com.
Source: FORUS Therapeutics
